Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis

Thursday, October 30, 2025

10:30 AM - 10:45 AM

Location: ROOM: Conference Room 4B >>> DIRECTIONS Fourth Floor >>> From the Main Elevator Bank, proceed left. Room 4D is at the end of the corridor, after taking a right just before Room 4-D. Walk past Room 4A; Room 4B is the second door on the right.

Non-presenting Author(s)

DM

Danielle Madison, DO

PGY-2
Lakeland Regional Medical Center
Lakeland, Florida, United States
AM

Adriana Morales Rivera, MD

PGY-2
Lakeland Regional Health
Lakeland, Florida, United States
DC

Dylon Collins, DO

PGY-1
Lakeland Regional Health
Lakeland, Florida, United States

Presenting Author(s)

IL

Isabel Lam, DO

PGY-1
Lakeland Regional Health
Lakeland, Florida, United States
DK

Daniel Khokhar, DO

PGY-1
Lakeland Regional Health
Lakeland, Florida, United States

Non-presenting Author(s)

GS

Garrett Synder, DO

PGY-1
Lakeland Regional Health
Lakeland, Florida, United States
AT

Anthony Thompson, MD

PGY-1
Lakeland Regional Health
Lakeland, Florida, United States
MS

Mark Soliman, MD

PGY-1
Lakeland Regional Health
Lakeland, Florida, United States
DC

Daniela Carralero Somoza, MD

PGY-3
Lakeland Regional Health
Lakeland, Florida, United States
MS

Michael Sabina, DO

PGY-3
Lakeland Regional Health
Lakeland, Florida, United States

Learning Objectives:

Upon completion, participants will be able to see how GLP-1RAs may be utilized for pain reduction in knee osteoarthritis.
Upon completion, participants will be able to recognize areas that GLP-1RAs may not provide significant benefit in knee osteoarthritis.
Upon completion, participants will be able to reason that weight loss through GLP-1RAs can contribute to improved knee osteoarthritis symptoms.